These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 27709117)
21. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868 [TBL] [Abstract][Full Text] [Related]
22. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804 [TBL] [Abstract][Full Text] [Related]
23. Analysis of the genetic variability in Parkinson's disease from Southern Spain. Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746 [TBL] [Abstract][Full Text] [Related]
24. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011 [TBL] [Abstract][Full Text] [Related]
25. Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada. Han F; Grimes DA; Li F; Wang T; Yu Z; Song N; Wu S; Racacho L; Bulman DE Int J Neurosci; 2016; 126(5):415-21. PubMed ID: 26000814 [TBL] [Abstract][Full Text] [Related]
26. Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population. Chen S; Liu H; Wu QQ; Xu SJ; Li WG; Chen T; Li C; Ma XY; Xu S; Liu YM Front Neurol; 2019; 10():1231. PubMed ID: 31824408 [TBL] [Abstract][Full Text] [Related]
27. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793 [TBL] [Abstract][Full Text] [Related]
28. Genetic Identification in Early Onset Parkinsonism among Norwegian Patients. Gustavsson EK; Trinh J; McKenzie M; Bortnick S; Petersen MS; Farrer MJ; Aasly JO Mov Disord Clin Pract; 2017; 4(4):499-508. PubMed ID: 30363439 [TBL] [Abstract][Full Text] [Related]
29. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086 [TBL] [Abstract][Full Text] [Related]
30. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. Aharon-Peretz J; Rosenbaum H; Gershoni-Baruch R N Engl J Med; 2004 Nov; 351(19):1972-7. PubMed ID: 15525722 [TBL] [Abstract][Full Text] [Related]
31. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296 [TBL] [Abstract][Full Text] [Related]
32. Comparison of elderly and young patient populations treated with deep brain stimulation for Parkinson's disease: long-term outcomes with up to 7 years of follow-up. Hanna JA; Scullen T; Kahn L; Mathkour M; Gouveia EE; Garces J; Evans LM; Lea G; Houghton DJ; Biro E; Bui CJ; Sulaiman OA; Smith RD J Neurosurg; 2018 Sep; 131(3):807-812. PubMed ID: 30265192 [TBL] [Abstract][Full Text] [Related]
33. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Moraitou M; Hadjigeorgiou G; Monopolis I; Dardiotis E; Bozi M; Vassilatis D; Vilageliu L; Grinberg D; Xiromerisiou G; Stefanis L; Michelakakis H Mol Genet Metab; 2011; 104(1-2):149-52. PubMed ID: 21745757 [TBL] [Abstract][Full Text] [Related]
34. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil. Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137 [TBL] [Abstract][Full Text] [Related]
35. Parkin mutation and deep brain stimulation outcome. Kim HJ; Yun JY; Kim YE; Lee JY; Kim HJ; Kim JY; Park SS; Paek SH; Jeon BS J Clin Neurosci; 2014 Jan; 21(1):107-10. PubMed ID: 24060625 [TBL] [Abstract][Full Text] [Related]